<DOC>
	<DOCNO>NCT01069120</DOCNO>
	<brief_summary>Safety efficacy study 25 50 mg dos Proellex</brief_summary>
	<brief_title>Safety 25 50 mg ProellexÂ® Treatment Women With Symptomatic Uterine Fibroids</brief_title>
	<detailed_description>The study intend provide abundant safety efficacy data 25 50 mg dos Proellex ZPU-301 , ZPU-302 , ZPU-303 ZPU-304 alone .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>At least 1 uterine fibroid must identifiable measurable Transvaginal Ultrasound ( TVU ) Subject menstrual cycle last 20 40 day . Subject must satisfactorily complete study visit previous study participate : ZPU301 , ZPU302 , ZPU303 , ZPU304 Subjects participate 1 previous Repros study : ZPU301 , ZPU302 , ZPU303 , ZPU304 . Subjects met treatment stop rule per DILI Guidance requirement participate ZPU301 , ZPU302 , ZPU303 , ZPU304</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uterine Fibroids</keyword>
</DOC>